← board
SGMOQ
distress 7/10 · high distress / dilution risk$0.06-9%today-91% from 52w high
Revenue
pre-revenue
Liquidity
$28M
Runway
0.3 yrs
Shares 1y
+37%
Price & events
-84.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-9.3%
1D
-9.3%
1W
-9.3%
1M
-75.6%
3M
-83.3%
6M
-88.5%
1Y
-84.1%
2Y
-99.4%
5Y
-99.6%
All
Overview
- Market Cap
- $26.31M
- Volume
- 25.90K
- 52 Week Range
- $0.04 – $0.74
- Total Shares
- 414.29M
- Float Shares
- 370.04M
- RVOL
- 0.00x
- Beta
- 1.42
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-08-06earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-02-10HC Wainwright & Co.Buy
Competitors
- none identified
Recent news
- 2026-07-15Sangamo Therapeutics (SGMO) Holds Steady at $0.07 Amidst Flat Trading - Weak Sell Signals - dars.gov.et
- 2026-06-26Sangamo Therapeutics updates pipeline strategy, shares trade on Nasdaq - Ad-hoc-news.de
- 2026-06-24SGMOQ Stock Price and Chart — OTC:SGMOQ - TradingView
- 2026-06-23Eli Lilly Enters Into Agreement to Acquire Sangamo Assets as Stalking Horse Bidder in Chapter 11 Auction - Paul, Weiss
- 2026-06-23Form 8K Sangamo Therapeutics Inc For: 23 June By Investing.com - Investing.com Canada
- 2026-06-23Sangamo Therapeutics (SGMO) Files for Chapter 11 Bankruptcy Prot - GuruFocus
- 2026-06-17Sangamo Therapeutics Inc (SGMO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
- 2026-06-17Sangamo Therapeutics Inc (SGMO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.